Evidence map›Paper›PMID 38645572›Full record

ArticleCase reports in oncology

Pembrolizumab in Vaginal Carcinoma: A Case Report and Review of the Literature.

Maria Giuseppa Vitale, Cecilia Nasso, Beatrice Riccò, Alessandro Bocconi, Chiara Chiavelli, Cinzia Baldessari, Stefania Pipitone, Francesca Bacchelli, Laura Botticelli, Massimo Dominici and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Targeted therapies in primary vaginal cancer.Journal of cancer research and clinical oncology · 2025
    Article
  2. Comprehensive management of vulvovaginal cancers.CA: a cancer journal for clinicians
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Maria Giuseppa VitaleDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Cecilia NassoDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Beatrice RiccòDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Alessandro BocconiDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Chiara ChiavelliDivision of Oncology, Department of Medical and Surgical Sciences for Children & Adults, Laboratory of Cellular Therapy, University of Modena and Reggio Emilia, Modena, Italy.
Cinzia BaldessariDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Stefania PipitoneDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Francesca BacchelliDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Laura BotticelliDepartment of Laboratory Medicine and Anatomy Pathology, Institute of Anatomy and Histology Pathology, University Hospital of Modena, Modena, Italy.
Massimo DominiciDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Roberto SabbatiniDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
University of Modena and Reggio Emilia · ITOspedale Santa Corona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Vaginal cancer is a rare gynecologic malignancy. While in a localized disease, concurrent chemoradiation grants local control and better overall survival, in a metastatic setting, the management options are very limited. Furthermore, recurrent cervical, vulvar, and vaginal carcinomas notoriously develop resistance to treatment, and consequently, their prognosis is still poor. Case Presentation: We herein present the case of a woman with a nodal relapse of vaginal carcinoma, effectively treated with third-line immunotherapy. We will also provide a review of the literature on the new therapeutic strategies for advanced vaginal carcinoma, with a focus on pembrolizumab immunotherapy. Conclusion: Pembrolizumab might represent a promising option for the management of vaginal and vulvar cancer, but data to support its use in this setting are still lacking. This case highlights the need for further investigation and trial designs for this rare disease.

Indexed as

Case reportImmunotherapyPembrolizumabVaginal cancerVulval cancer

Identifiers

PMID38645572
PMCPMC11032179
OpenAlexW4394993017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.